This site is intended for healthcare professionals
Drug information

Aciclovir

POM
Read time: 18 mins
Last updated: 06 May 2020
Published: 01 Apr 2021

4.1 Therapeutic indications

Aciclovir 25 mg/ml Concentrate for Solution for Infusion is indicated for the treatment of severe initial genital herpes in the immunocompromised and the non-immunocompromised.

Aciclovir 25 mg/ml Concentrate for Solution for Infusion is indicated for the prophylaxis and treatment of Herpes simplex infections in immunocompromised patients.

Aciclovir 25 mg/ml Concentrate for Solution for Infusion is indicated for the treatment of Varicella zoster infections.

Aciclovir 25 mg/ml Concentrate for Solution for Infusion is indicated for the treatment of herpes encephalitis.

Aciclovir 25 mg/ml Concentrate for Solution for Infusion is indicated for the treatment of Herpes simplex infections in the neonate and infant up to 3 months of age.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).